StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
BRNSBarinthus Biotherapeutics plc.
stockpulse.co.kr
Nasdaq
$0.7401▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $30.2MShares out 40.9M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

24
  • 9.21After-hours26.09.22 05:15
    15-12GOther#●●●

    Barinthus Biotherapeutics plc.Bullish

    Barinthus Biotherapeutics plc has filed Form 15-12G to terminate the registration of its securities and suspend its reporting obligations under the U.S. Securities Exchange Act. The company reported that the number of record holders is one, effectively ending its SEC reporting duties.…more

    $0.7401+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.15Pre-market26.09.15 13:15filed
    EFFECTOther

    Barinthus Biotherapeutics plc.

    Barinthus Biotherapeutics plc. received SEC effectiveness approval for its registration statement on September 14, 2026. This effectiveness allows the company to officially proceed with the securities offering or capital raising activities outlined in the filing.…more

    $0.7401+0.00%vs prev close
    View filingShare
  • 9.11Regular26.09.12 00:47
    SCHEDULE 13G/AOwnership

    Barinthus Biotherapeutics plc.

    Oxford Science Enterprises plc has filed a SCHEDULE 13G/A regarding its beneficial ownership in Barinthus Biotherapeutics plc. This filing serves as an update to the reporting entity's equity position in the company.…more

    $0.7401+0.00%vs prev close
    View filingShare

23 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire

No news collected yet. New articles will appear here.